...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Pfizer

Nice find Iconoclast.

I would say Zenith fits this initiative like a glove.  ZEN-3694 is all about Oncology.

 

Zenith has a successful Phase 2 trial completed for Prostate cancer.  What % of Zenith would the board consider selling Pfizer for $500 Million?  My number is no more than 25% with the stipulation that Zenith pays out a special dividend with $400 Million to shareholders.  Tidy payday for shareholders hanging on for 7 years and $100 Million for Zenith to fund a Nasdaq listing, more trials and research.

 

my 2 cents

Share
New Message
Please login to post a reply